Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Vaccinations, testing demand power Walgreens forecast raise

Published 01/06/2022, 07:19 AM
Updated 01/06/2022, 12:30 PM
© Reuters. FILE PHOTO: A person rides past a Walgreens truck, owned by the Walgreens Boots Alliance, Inc., in Manhattan, New York City, U.S., November 26, 2021. REUTERS/Andrew Kelly

By Manojna Maddipatla and Oishee Majumdar

(Reuters) - Walgreens Boots Alliance (NASDAQ:WBA) Inc raised its full-year adjusted profit growth forecast and said it expects to administer 5 million more COVID-19 vaccines as the fast-spreading Omicron variant rages across the United States.

The company administered 15.6 million vaccinations and 6.5 million tests in the first quarter, helping U.S. same-store retail sales notch their best performance in over two decades.

Executives on a post-earnings call on Thursday sounded confident in the supply of at-home tests after the spike in new cases forced the company, Walmart (NYSE:WMT) Inc and CVS Health Corp (NYSE:CVS) to limit sales of such kits.

"We see our stock availability levels going up significantly by mid-month. So, we're feeling in a pretty good place in the next three months," Chief Financial Officer James Kehoe said, without providing further details.

Walgreens now expects to administer 30 million vaccinations at its stores in fiscal 2022, adding the number could be higher based on the evolution of the Omicron variant and regulatory guidance.

While there could be a potential positive impact on earnings due to the new vaccination target for the year, management's comments suggest there could be potential challenges from labor investments, Cowen analyst Charles Rhyee said.

Walgreens, which has administered over 56 million vaccines so far, said it would invest about $120 million in employees, as it seeks to battle staffing shortages and temporary operating hour reductions.

In September, the company said it would give a one-time bonus of $1,250 to its full-time pharmacists and a $1,000 payment to part-time pharmacists.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

For the first quarter, Walgreens posted an adjusted profit of $1.68 per share, easily beating estimates of $1.33.

The company, which reported sales of $51 million in its newly created Walgreens Health unit, also increased its full-year adjusted profit expectations to low-single digit growth from flat.

Shares of the company were down about 1% at $53.25.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.